September 15, 2008
EDAP’s HIFU Technology Highlighted At the 8th Annual International Symposium On Therapeutic Ultrasound
LYON, France, Sept. 15, 2008 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that its High Intensity Focused Ultrasound (HIFU) technology was highlighted at the 8th Annual International Symposium on Therapeutic Ultrasound (ISTU) from September 10-13, 2008 in Minneapolis, Minnesota.
ISTU is an annual gathering of the scientific and medical communities that provides an overview and basic background on the clinical uses of ultrasound therapy. The scientific and educational goals of the symposium are to allow researchers, clinical users and device manufacturers to assess current state-of-the-art developments in therapeutic ultrasound applications and to share their insights on HIFU non-invasive applications.
ISTU provided EDAP with the opportunity to present the Company's data and latest advancements in the uses of HIFU. Dr. Gelet, from Edouard Herriot Hospital, Lyon, France, and Dr. Blana, from Regensburg Hospital, Germany, presented clinical results and highlighted their experiences using HIFU to address localized prostate cancer. In addition, EDAP's collaborator INSERM discussed data on therapeutic ultrasound from several studies highlighting the clinical benefits of such a minimally invasive approach.
Marc Oczachowski, EDAP's Chief Executive Officer, said, "The ISTU meeting provided EDAP with a unique opportunity to present our experiences and confirm our position as one of the leading research and clinical teams in HIFU therapy worldwide. Our presentations at ISTU clearly highlighted EDAP's continued advancement and worldwide leadership position in HIFU treatment exemplified by the Company's significant experience and almost 17,000 treatments performed at more than 190 centers. The symposium confirmed HIFU as an effective therapeutic option in the treatment of localized prostate cancer and highlighted the technology's potential to become the standard of care across multiple indications. With our solid IP portfolio, demonstrated experience and INSERM's continuous support, we are very well positioned to participate in the development of future minimally invasive HIFU options that will benefit all patients. We will continue to leverage our position as the global leader in therapeutic ultrasound to support and lead the growth of HIFU in prostate cancer and beyond."
About EDAP TMS SA
EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit http://www.edap-tms.com, http://www.hifu-planet.com and http://www.pcaresearch.com or http://www.urotoday.com/HIFU.
In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or marketed in the United States.
This news release was distributed by GlobeNewswire, www.globenewswire.com
CONTACT: EDAP TMS SA Investor Relations/Legal Affairs: Blandine Confort +33 4 72 15 31 72 [email protected] The Ruth Group Investors: R.J. Pellegrino 646-536-7009 [email protected]